Vaginitis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Vaginitis refers to the inflammation of vagina. It affects women of all ages but is most common during the reproductive years. Vaginitis occurs due to change in the balance of the yeast and bacteria that normally live in the vagina. This causes the lining of the vagina to become inflamed. Use of antibiotics, changes in hormone levels due to pregnancy, breastfeeding, menopause, douching, spermicides, sexual intercourse and infection can change the normal balance of the vagina. The main symptom of vaginitis is increased discharge with a strong fishy odour. Itching is not common, but may be present if there is a lot of discharge. Vaginitis can be diagnosed by taking a sample of the discharge from vagina, which is then observed under a microscope. The treatment depends on the cause of the vaginitis. It may include a pill or a cream or gel that is applied to the vagina.

The drug candidates in vaginitis pipeline include, but are not limited to, Polygynax and Tamoxifen vaginal. Some of the companies in vaginitis therapeutics pipeline are Lumavita AG and Fulhold Pharma Limited.

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.